1. Home
  2. QDEL vs MESO Comparison

QDEL vs MESO Comparison

Compare QDEL & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$29.83

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$18.50

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
MESO
Founded
1979
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
QDEL
MESO
Price
$29.83
$18.50
Analyst Decision
Hold
Strong Buy
Analyst Count
6
2
Target Price
$39.33
$24.00
AVG Volume (30 Days)
1.2M
195.5K
Earning Date
11-05-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,714,400,000.00
$17,198,000.00
Revenue This Year
N/A
$465.44
Revenue Next Year
$2.42
$75.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
191.39
52 Week Low
$19.50
$9.61
52 Week High
$49.45
$22.00

Technical Indicators

Market Signals
Indicator
QDEL
MESO
Relative Strength Index (RSI) 65.19 63.70
Support Level $26.84 $16.43
Resistance Level $28.30 $17.65
Average True Range (ATR) 1.31 0.63
MACD 0.50 0.32
Stochastic Oscillator 93.41 82.57

Price Performance

Historical Comparison
QDEL
MESO

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: